viewDirecta Plus PLC

Directa Plus PLC - R&D Agreement with Comerio Ercole

RNS Number : 2379A
Directa Plus PLC
20 January 2020

20 January 2020


Directa Plus plc

("Directa Plus" or the "Company")


R&D Agreement with Comerio Ercole


Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that it has signed an agreement with Comerio Ercole SpA ("Comerio") to pursue joint research and development projects using the Company's G+ technology to develop products in the rubber and tyres, plastic and non-woven materials industries.


Comerio is a leading Italian engineering and manufacturing company, founded in 1885, specialising in rubber and composite material processing and in the machinery used to manufacture such products. The company is well known globally for its focus on innovation, quality and environmental protection.  The partners will use Comerio's own R&D laboratory, with mixing and calendering machinery, to explore prototype processes using polymers and elastomers that could in future be useful to produce and improve compounds containing G+.


Directa Plus is interested both in testing its G+ technology in polymer and elastomer manufacture and in promoting its activity and products to end customers and users of Comerio machinery and plants.


In addition, there may be opportunities to take part in events and exhibitions attended by Comerio.


Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said: "Working with selected partners who share our vision for product development is a great way to bring graphene enhanced products to market in partnership with established Italian, European, and global companies.  Combining Comerio's deep expertise in materials and machinery with our world leading knowledge and understanding of graphene, will help create new market opportunities for both our companies."


Riccardo Comerio, CEO of Comerio Ercole, added: "Comerio Ercole has always been a pioneer in the field of industrial innovation for mixing and calendering processes. With Directa Plus we are now undertaking an exciting new challenge to identify the most promising uses of graphene in our machinery and plants for selected, qualified customers. Based on our laboratory experience, our target is to develop,  tailored industrial machinery for specific graphene applications."


For further information please visit http://www.directa-plus.com/ or contact:


Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO


Marco Ferrari, CFO




Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)

+44 20 7894 7000

Rick Thompson, Philip Davies, Will Goode(Corporate Finance)


Caspar Shand Kydd (Sales)




N+1 Singer (Joint Broker)

+44 20 7496 3069

Mark Taylor, Lauren Kettle




Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson, Barney Hayward, Edward Lee



About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products).  In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products.  All our products are hypoallergenic, non-toxic and sustainably produced.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Directa Plus PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Market Report: FTSE jumps on AstraZeneca COVID-19 vaccine trial and easing...

FTSE 100 rallied in early trading on AstraZeneca’s COVID-19 vaccine trial and the easing of lockdown restrictions from December. London’s blue-chip index rose 20 to 6,371. AstraZeneca PLC (LON:AZN) announced that the coronavirus (COVID-19) vaccine it has developed with Oxford University was...

4 days, 9 hours ago

4 min read